2024-517547-31-00RecruitingPhase 1
A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- First submitted
- 16 Dec 2024
- Start date
- 31 Jan 2025
- Lead sponsor
- Aboleris Holdco
- Diseases
- Rheumatoid arthritis
- EU CT number
- 2024-517547-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 78
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Recruiting |
| Centre Hospitalier Universitaire de Liège | Liège | Belgium | Recruiting |
| Universitaetsklinikum Erlangen AöR | Erlangen | Germany | Recruiting |
| Fraunhofer Institute For Translational Medicine And Pharmacology ITMP | Frankfurt Am Main | Germany | Recruiting |
| Centre for Human Drug Research | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.